Symbiosis Reaches Major Milestone With Injectable Drug Product
Symbiosis Pharmaceutical Services recently announced the successful completion of its 1,000th sterile drug product batch, marking a significant milestone in its mission to accelerate access to life-changing medicines worldwide.
Since the company was founded in 2011, Symbiosis has grown from a Scottish start-up into an internationally recognised sterile manufacturer of injectable drug products, supporting both clinical development and commercial supply across a wide range of therapeutic areas.
Over the past 14 years, the company has delivered complex injectable products spanning monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), viral vectors, small molecules, and advanced therapy medicinal products (ATMPs).
Symbiosis played a pivotal role in the clinical development of the Oxford University/AstraZeneca COVID-19 vaccine, manufacturing nearly one million doses at its Stirling facility to support clinical trials and enable accelerated regulatory approval in the UK.
Today, Symbiosis supports clients through Phase 1, 2, and 3 clinical trials and commercial-scale manufacturing across the globe.
“Reaching our 1,000th batch is a proud moment for everyone at Symbiosis,” said Colin MacKay, CEO of Symbiosis. “As global demand for sterile drug products rises, it reflects our commitment to manufacturing excellence and our shared purpose of helping deliver life-saving medicines to patients faster.”
Symbiosis has maintained a consistent track record of successful GMP inspections from regulatory agencies including the US FDA and UK MHRA since the company began, underscoring its reputation for regulatory compliance and manufacturing excellence.
“2025 has been a landmark year for Symbiosis; winning the King’s Award for Enterprise in International Trade to launching our new automated commercial-scale manufacturing facility in Stirling,” Colin added. “Symbiosis will continue to build upon this momentum, helping more clients deliver innovative medicines to patients around the world.”
Symbiosis Pharmaceutical Services (Symbiosis) is a world-class Contract Manufacturing Organisation (CMO) located in Stirling, UK, and is a specialist sterile GMP manufacturer of biopharmaceuticals for use in clinical trials and commercial sales globally. Symbiosis is MHRA-licensed and FDA-inspected and offers a range of services including the aseptic fill/finish of medicines into vials, analytical testing, QP release of product, inspection, labelling, packaging and GMP temperature-controlled storage and shipment of medicines.
The Symbiosis facilities in Stirling, Scotland, are designed for biologic and small molecule pharmaceutical production to support biotechnology and pharmaceutical companies worldwide requiring sterile injectable pharmaceutical products manufactured in short timeframes for clinical trial use and commercial supply.
Regulatory compliance, technical capability and operational flexibility are core to the Symbiosis value proposition along with direct access to a highly experienced team of life science experts. By adding value directly to the new drug development projects and the commercial manufacturing supply chain requirements of its clients, Symbiosis has demonstrated consistent annual growth and built long-term relationships with its client base globally. For more information, visit http://www.symbiosis-pharma.com.
Total Page Views: 258